含Advax-SM佐剂的M2蛋白通用流感疫苗可通过母体或新生儿免疫保护新生小鼠
研究在小鼠中评估含Advax-SM佐剂的M2e流感疫苗(CapM2e)对新生儿的保护效果,采用母体免疫被动转移和新生儿直接免疫两种策略。母体免疫诱导高水平M2e抗体并被动转移给后代,使3周龄小鼠抵抗H1N1和H3N2攻击;新生儿直接免疫同样诱导高血清M2e抗体并保护免受H1N1和H3N2攻击,保护与抑制病毒复制及显著降低肺病毒载量相关。结论提示该疫苗候选可通过母体或新生儿免疫保护新生儿对抗多种甲型流感毒株。
要点
- 母体接种CapM2e+Advax-SM可被动转移M2e抗体,保护3周龄后代抵抗H1N1和H3N2。
- 新生儿直接接种CapM2e+Advax-SM诱导高血清M2e抗体并抵抗H1N1和H3N2攻击。
- 保护与抑制病毒复制及显著降低肺病毒载量相关。
核心结论
- CapM2e+Advax-SM疫苗可通过母体被动免疫或新生儿主动免疫保护新生小鼠对抗多种甲型流感毒株。
研究设计与样本
- 小鼠研究:母体免疫组雌鼠在交配前1周和交配后免疫,断奶时采集母鼠和后代血,后代3周龄时用致死剂量H1N1和同源重配H3N2攻击。
- 新生儿直接免疫组在1周龄和3周龄免疫,4周龄攻击前采血。
主要发现
- 母体免疫诱导高水平母体M2e抗体并被动转移给后代,3周龄攻击时保护抵抗H1N1和H3N2。
- 新生儿直接免疫诱导高血清M2e抗体,保护抵抗H1N1和H3N2攻击。
- 保护与抑制病毒复制相关,免疫幼鼠肺病毒载量显著降低。
临床怎么用
- 提示M2e疫苗候选可通过母体免疫或新生儿免疫为6月龄以下婴儿提供潜在保护策略。
- 支持进一步开发该M2e基通用流感疫苗候选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite newborns being at increased risk of serious influenza infection, influenza vaccines are currently not recommended for use in infants under 6 months of age. We therefore sought to evaluate the protective efficacy in mice of an M2-based influenza vaccine (CapM2e) formulated with Advax-SM adjuvant. Vaccine protection was assessed via both passive maternal immunization and direct neonatal immunization. METHODS: For maternal transfer studies, female mice were immunized 1 week before and after mating. Blood was collected from both mother and offspring during weaning and pups were challenged when they reached 3 weeks of age with lethal doses of H1N1 and homologous reassortment influenza strain H3N2 with conserved M2. For direct immunization studies, newborns were immunized at 1 and 3 weeks of age and blood was collected prior to challenge at 4 weeks of age. RESULTS: Maternal immunization with CapM2e + Advax-SM vaccine induced high maternal M2e antibody levels that were passively transferred to their offspring and provided them with protection against both H1N1 and H3N2 influenza strains when challenged at 3 weeks of age. When used for direct immunization of neonatal mice, CapM2e + Advax-SM vaccine similarly induced high serum M2e antibody levels and protected against H1N1 and H3N2 influenza challenges with protection associated with inhibition of virus replication with a significant reduction in lung virus load in immunized pups. CONCLUSION: CapM2e + Advax-SM vaccine could be useful for protecting newborns against diverse influenza A strains, with opportunities to achieve protection by passive maternal immunization or active neonatal immunization. This data supports further development of this promising M2e-based vaccine candidate.
引用
- Sakala IG, Honda-Okubo Y, Li L, et al. A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization. Vaccine. 2021. PMID: 34362601. doi:10.1016/j.vaccine.2021.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。